Skip to main content
Premium Trial:

Request an Annual Quote

Lynx s CEO Russell Abruptly Resigns; VP Named as Replacement

NEW YORK, June 4 - Norrie Russell, the acerbic president and CEO of Lynx Therapeutics, has resigned, the company said today.


Kevin Corcoran, vice president of operations at Hayward, Calif.-based Lynx and a veteran of Applied Biosystems, was named as a replacement.


Though it was not immediately clear why Russell left--Lynx said he split "to pursue other interests"--a more accurate reason may be the company's financial outlook: Though it reported strong increase in first-quarter revenues and a narrowed net loss, Lynx had total cash, cash equivalents, and short-term investments of just under $2 million as of March 31.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.